{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T05:04:01Z","timestamp":1790744641675,"version":"4.1.0"},"reference-count":20,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:00:00Z","timestamp":1790726400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Acquired hemophilia A (AHA) usually causes cutaneous, soft-tissue, or muscle bleeding; joint-dominant presentations are uncommon and may be mistaken for septic or inflammatory arthritis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>A man in his late 60s with no personal or family bleeding history developed recurrent arthritis-like joint swelling, extensive bruising, and suspected iliopsoas, upper-arm, and thigh hematomas after an elective operation. For approximately 4 months, fever, raised inflammatory markers, and periarticular imaging abnormalities led to repeated infection-directed treatment. At specialist assessment, the activated partial thromboplastin time was 77.6\u2005s. A mixing study showed greater prolongation after incubation, factor VIII activity was below 0.8%, and the factor VIII inhibitor titer exceeded 120 Bethesda units, establishing AHA. Intravenous methylprednisolone followed by a prednisone taper and two rituximab infusions was followed by cessation of new bleeding and improvement in joint symptoms. At approximately 5 months after starting immunosuppression, the inhibitor was undetectable, factor VIII activity had recovered to 27%, and the activated partial thromboplastin time was within the reporting laboratory's reference range. At telephone follow-up approximately 13 months after treatment began, he reported clinical stability for about 6 months after stopping all medications, apart from occasional brief right-knee pain; contemporaneous coagulation results were unavailable. Repeated ceftriaxone exposure was considered a possible associated factor, but causality was not established because an activated partial thromboplastin time of 40\u2005s was documented before the first recorded postoperative exposure and later antibiotic exposures were incompletely documented.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In an older adult, recurrent hot or swollen joints accompanied by deep-muscle bleeding and an unexplained prolonged activated partial thromboplastin time should prompt immediate factor VIII activity and inhibitor testing. This case documents inhibitor clearance with partial factor VIII recovery and subsequent patient-reported stability off treatment; it does not prove drug causality or the comparative efficacy of rituximab.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2026.1964024","type":"journal-article","created":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T04:47:59Z","timestamp":1790743679000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Case Report: Acquired hemophilia A presenting with recurrent arthritis-like joint swelling and musculoskeletal hematomas\u2014a focused literature review"],"prefix":"10.3389","volume":"13","author":[{"given":"Jing","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Rheumatology and Immunology, Peking University International Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lina","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, Peking University International Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng-Guang","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, Peking University International Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, Peking University International Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yadan","family":"Zou","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, Peking University International Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Long","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, Peking University International Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruohan","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, Peking University International Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanfeng","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, Peking University International Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,30]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.3324\/haematol.2019.230771","article-title":"International recommendations on the diagnosis and treatment of acquired hemophilia A","volume":"105","author":"Tiede","year":"2020","journal-title":"Haematologica"},{"key":"B2","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1111\/j.1538-7836.2012.04654.x","article-title":"Demographic and clinical data in acquired hemophilia A: results from the European acquired haemophilia registry (EACH2)","volume":"10","author":"Knoebl","year":"2012","journal-title":"J Thromb Haemost"},{"key":"B3","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1111\/bjh.70200","article-title":"Laboratory investigation and clinical management of acquired coagulation factor inhibitors: a joint British society for haematology and United Kingdom haemophilia centre doctors\u2019 organisation guideline","volume":"208","author":"Percy","year":"2026","journal-title":"Br J Haematol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1016\/S1297-319X(03)00057-5","article-title":"Hemarthrosis in acquired hemophilia: two case reports","volume":"70","author":"Wendling","year":"2003","journal-title":"Jt Bone Spine"},{"key":"B5","doi-asserted-by":"publisher","first-page":"e12044","DOI":"10.1097\/MD.0000000000012044","article-title":"Successful treatment of acquired hemophilia A associated with immune thrombocytopenia and joint hemarthrosis: a case report and literature review","volume":"97","author":"Wei","year":"2018","journal-title":"Medicine (Baltimore)"},{"key":"B6","doi-asserted-by":"publisher","first-page":"e95170","DOI":"10.7759\/cureus.95170","article-title":"Spontaneous hemarthrosis and compartment syndrome in an elderly female with acquired hemophilia A: a case report","volume":"17","author":"Alam","year":"2025","journal-title":"Cureus"},{"key":"B7","doi-asserted-by":"publisher","first-page":"V23","DOI":"10.5070\/M5.52344","article-title":"Hematoma, hemarthrosis, and hemotympanum: a case report of acquired hemophilia A","volume":"11","author":"Wolff","year":"2026","journal-title":"J Educ Teach Emerg Med"},{"key":"B8","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1182\/hematology.2023000460","article-title":"Diagnosis and laboratory monitoring of acquired hemophilia A","volume":"2023","author":"Platton","year":"2023","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"B9","first-page":"RA55","article-title":"Drug-induced anti-factor VIII antibodies: a systematic review","volume":"13","author":"Franchini","year":"2007","journal-title":"Med Sci Monit"},{"key":"B10","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1111\/hae.14692","article-title":"Drug-associated acquired hemophilia A: an analysis based on 185 cases from the WHO pharmacovigilance database","volume":"29","author":"Konstantinov","year":"2023","journal-title":"Haemophilia"},{"key":"B11","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1186\/s12893-020-00872-y","article-title":"Surgery-associated acquired hemophilia A: a report of two cases and review of the literature","volume":"20","author":"Khan","year":"2020","journal-title":"BMC Surg"},{"key":"B12","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1182\/blood-2012-02-408930","article-title":"Management of bleeding in acquired hemophilia A: results from the European acquired haemophilia registry (EACH2)","volume":"120","author":"Baudo","year":"2012","journal-title":"Blood"},{"key":"B13","doi-asserted-by":"publisher","first-page":"e948268","DOI":"10.12659\/AJCR.948268","article-title":"Endovascular embolization in acquired hemophilia A: a case study highlighting diagnostic and therapeutic strategies","volume":"26","author":"Makris","year":"2025","journal-title":"Am J Case Rep"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1182\/blood-2014-07-587089","article-title":"Prognostic factors for remission of and survival in acquired hemophilia A: results from the GTH-AH 01\/2010 study","volume":"125","author":"Tiede","year":"2015","journal-title":"Blood"},{"key":"B15","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1182\/blood-2012-02-409185","article-title":"Immunosuppression for acquired hemophilia A: results from the European acquired haemophilia registry (EACH2)","volume":"120","author":"Collins","year":"2012","journal-title":"Blood"},{"key":"B16","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1002\/ajh.27128","article-title":"Single-dose rituximab plus glucocorticoid versus cyclophosphamide plus glucocorticoid in patients with newly diagnosed acquired hemophilia A: a multicenter, open-label, randomized noninferiority trial","volume":"99","author":"Wang","year":"2024","journal-title":"Am J Hematol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.thromres.2024.03.012","article-title":"Cyclophosphamide vs rituximab for eradicating inhibitors in acquired hemophilia A: a randomized trial in 108 patients","volume":"237","author":"L\u00e9vesque","year":"2024","journal-title":"Thromb Res"},{"key":"B18","doi-asserted-by":"publisher","first-page":"e913","DOI":"10.1016\/S2352-3026(23)00280-6","article-title":"Emicizumab prophylaxis in patients with acquired haemophilia A (GTH-AHA-EMI): an open-label, single-arm, multicentre, phase 2 study","volume":"10","author":"Tiede","year":"2023","journal-title":"Lancet Haematol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1016\/j.jtha.2022.10.004","article-title":"A prospective, multicenter, open-label phase III study of emicizumab prophylaxis in patients with acquired hemophilia A","volume":"21","author":"Shima","year":"2023","journal-title":"J Thromb Haemost"},{"key":"B20","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1055\/a-2197-9738","article-title":"Emicizumab for the treatment of acquired hemophilia A: consensus recommendations from the GTH-AHA working group","volume":"44","author":"Pfrepper","year":"2024","journal-title":"Hamostaseologie"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1964024\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T04:48:23Z","timestamp":1790743703000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1964024\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,30]]},"references-count":20,"alternative-id":["10.3389\/fmed.2026.1964024"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1964024","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,30]]},"article-number":"1964024"}}